Most Clicked StoriesMore >


Dr. Reddy's accused of drug-packaging violations in U.S.

DIA Global SmartBrief | Aug 26, 2014

The U.S. Consumer Product Safety Commission is considering civil penalties against Dr. Reddy's Laboratories for allegedly disobeying rules designed to stop children from ingesting dangerous substances, the Indian drugmaker said this week in a U.S. stock exchange filing. Dr. Reddy's has been in talks with the regulator over claims that between 2008 and 2012 it violated packaging regulations for certain prescription treatments. Reuters (08/21)


U.S. Justice Department ends probe of AstraZeneca's Brilinta trial

DIA Global SmartBrief | Aug 21, 2014

Antibacterial gel could eliminate resistant superbugs

DIA Global SmartBrief | Aug 21, 2014

EU notified body plans program of surprise audits

DIA Global SmartBrief | Aug 21, 2014

Roche boosts respiratory drug pipeline with $8.3B InterMune buy

DIA Global SmartBrief | Aug 26, 2014

Japanese drugmaker rebuffs reports of Roche's $10B buyout offer

DIA Global SmartBrief | Aug 21, 2014

TB group licenses drugs from Novartis

DIA Global SmartBrief | Aug 21, 2014

NHS OKs wider use of Viagra after price falls

DIA Global SmartBrief | Aug 26, 2014

Price caps hurt innovation, patients' access to drugs

DIA Global SmartBrief | Aug 21, 2014

CDC updates influenza vaccine recommendations

DIA Global SmartBrief | Aug 26, 2014


Find DIA Global SmartBrief Issues by Date:



DIA News More >


Check out the latest Global Forum article

DIA Global SmartBrief | Aug 28, 2014

Time running out for introductory offer on new Drug Safety eLearning Program

DIA Global SmartBrief | Aug 28, 2014

Program available for conference on The Future of Indian Healthcare: Patients Access and Innovation

DIA Global SmartBrief | Aug 26, 2014

Explore innovations, technologies and regulations surrounding biosimilars

DIA Global SmartBrief | Aug 21, 2014

Looking for tips on developing regulatory strategies in emerging markets?

DIA Global SmartBrief | Aug 19, 2014




Sign up for DIA Global SmartBrief



Designed specifically for the global drug development professional, the DIA Global SmartBrief is a FREE, twice weekly e-mail newsletter. By providing the latest need-to-know industry news and information, the DIA Global SmartBrief saves you time and keeps you smart. Learn more